Ochre Bio CSO Quin Wills (L) and CEO Jack O'Meara

Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

Boehringer In­gel­heim is pay­ing Ochre Bio $35 mil­lion in up­front and near-term pay­ments to dis­cov­er new treat­ments for chron­ic liv­er dis­eases like meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.